| scholarly article | Q13442814 |
| P356 | DOI | 10.1081/CNV-120016399 |
| P698 | PubMed publication ID | 12643005 |
| P50 | author | Fabrice Carrat | Q42226814 |
| Thierry André | Q56250413 | ||
| Erick Gamelin | Q114435588 | ||
| P2093 | author name string | Jean-Christophe Vaillant | |
| Christophe Louvet | |||
| Aimery de Gramont | |||
| Jean Cady | |||
| Frédéric Mal | |||
| Karine Beerblock | |||
| May Mabro | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line | Q41152639 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer | Q70753009 | ||
| P433 | issue | 1 | |
| P921 | main subject | hydroxycarbamide | Q212272 |
| fluorouracil | Q238512 | ||
| cisplatin | Q412415 | ||
| P304 | page(s) | 14-20 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Cancer Investigation | Q325953 |
| P1476 | title | Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). | |
| P478 | volume | 21 |
| Q49895422 | 5 fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane |
| Q49645479 | A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer |
| Q33398040 | Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer |
| Q37787578 | Hydroxyurea (therapeutics and mechanism): Metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications |
| Q80676121 | Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy |
| Q38113822 | Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis |
| Q33849290 | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data |
| Q33371241 | Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review |
| Q43206575 | Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer |
| Q79291006 | Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy |
| Q36964966 | Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? |
Search more.